Skip to main content

FDA Issues Class-Wide Labeling Changes for Testosterone Products

Medically reviewed by Judith Stewart, BPharm. Last updated on March 4, 2025.

February 28, 2025 -- Today, FDA informed sponsors of testosterone products about new labeling changes following the agency’s review of the findings from the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) clinical trial and the results from required postmarket ambulatory blood pressure (ABPM) studies.

Led by the TRAVERSE trial’s results, FDA is recommending changes to current labeling language, to include:

Led by results of the ABPM studies, FDA is also requiring changes to current labeling language, to include:

Testosterone, a hormone essential to the development of male growth and masculine characteristics, is approved solely for use in men who lack or have low testosterone levels in conjunction with an associated medical condition. Current FDA-approved testosterone formulations include oral, topical gel, transdermal patch, buccal system (applied to upper gum or inner cheek), and injection.

FDA first convened a Joint Meeting of the Bone, Reproductive and Urologic Drugs and the Drug Safety and Risk Management Advisory Committee in September 2014 following increased reports of stroke, heart attack, and death in men taking FDA-approved testosterone products. This meeting resulted in the agency’s recommendation for an industry-wide clinical trial to assess the safety of use in men with age-related hypogonadism (insufficient sex hormone production). Results from the TRAVERSE trial were submitted in 2023, concluding that there was no increase in the risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism.

Additionally, in 2016 and 2017, FDA recommended ABPM studies as part of the premarket development of two different testosterone products, administered by two different routes (subcutaneous injection and oral). Consistent results from the premarket ABPM studies of the two products raised concerns that use of testosterone products could lead to increased blood pressure. In March 2018, FDA also issued a postmarket requirement that individual ABPM studies be conducted for all testosterone products. Results from the completed ABPM studies confirmed an increase in blood pressure with use of all testosterone products, class-wide.

Today’s action follows several prior FDA actions regarding the safety of testosterone products, including a January 2014 Drug Safety Communication (DSC) warning of reported risks of stroke, heart attack, and death in men taking FDA-approved testosterone products; and a March 2015 DSC informing of required labeling changes and urging caution when using testosterone products for low testosterone due to aging.

FDA encourages health care professionals and patients to report adverse events or quality problems experienced with the use of any medication to FDA’s MedWatch Adverse Event Reporting program:

Source: FDA

Posted February 2025

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.